LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2025, detailing a period of significant transformation. The company advanced its lead compound LB-100, a first-in-class PP2A inhibitor, expanded clinical trials to additional sites with increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance its cancer treatment platform, and raised more than $11 million to strengthen its balance sheet.
The filing underscores LIXTE's progress in oncology drug development. LB-100, currently in proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma, has shown tolerability at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to enhance chemotherapies and immunotherapies, representing a new treatment paradigm in activation lethality. The company's novel approach is covered by a comprehensive patent portfolio.
Through its wholly owned subsidiary Liora Technologies Europe Ltd., LIXTE is also pioneering electronically controlled proton therapy systems for tumor treatment. The LiGHT System, Liora's proprietary technology, is believed to offer significant advantages over existing proton therapy technologies.
For further details, the full press release is available at https://ibn.fm/LP6QH. Additional information about the company can be found at www.lixte.com.
